Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Mar 10;12(1):4199.
doi: 10.1038/s41598-022-08089-0.

Chronic use of inhaled corticosteroids in patients admitted for respiratory virus infections: a 6-year prospective multicenter study

David Luque-Paz  1   2   3 , Pierre Tattevin  4   5   6 , Paul Loubet  7   8   9 , François Bénézit  4 , Vincent Thibault  10 , Fabrice Lainé  6   9 , Philippe Vanhems  11   12 , Selilah Amour  11 , Bruno Lina  13 , Xavier Duval  9   14 , Anne-Sophie L'Honneur  15 , Nadhira Fidouh  16 , Christine Vallejo  17 , Sophie Alain  18 , Florence Galtier  19 , Vincent Foulongne  20 , Gisèle Lagathu  10 , Nezha Lenzi  9 , Zineb Lesieur  9 , Odile Launay  9   21   22   23 , Stéphane Jouneau  24   25 ; FLUVAC Study Group
Collaborators, Affiliations
Multicenter Study

Chronic use of inhaled corticosteroids in patients admitted for respiratory virus infections: a 6-year prospective multicenter study

David Luque-Paz et al. Sci Rep. .

Abstract

Inhaled corticosteroids (ICS) have been associated with increased risk of pneumonia. Their impact on respiratory virus infections is unclear. We performed a post-hoc analysis of the FLUVAC cohort, a multicenter prospective cohort study of adults hospitalized with influenza-like illness (ILI) during six consecutive influenza seasons (2012-2018). All patients were tested for respiratory virus infection by multiplex PCR on nasopharyngeal swabs and/or bronchoalveolar lavage. Risk factors were identified by logistic regression analysis. Among the 2658 patients included, 537 (20.2%) were treated with ICS before admission, of whom 282 (52.5%, 282/537) tested positive for at least one respiratory virus. Patients on ICS were more likely to test positive for non-influenza respiratory viruses (25.1% vs. 19.5%, P = 0.004), especially for adenovirus (aOR 2.36, 95% CI 1.18-4.58), and respiratory syncytial virus (aOR 2.08, 95% CI 1.39-3.09). Complications were reported in 55.9% of patients on ICS (300/537), primarily pneumonia (171/535, 32%). Among patients on chronic ICS who tested positive for respiratory virus, 14.2% (40/282) were admitted to intensive care unit, and in-hospital mortality rate was 2.8% (8/282). Chronic use of ICS is associated with an increased risk of adenovirus or RSV infections in patients admitted for ILI.

PubMed Disclaimer

Conflict of interest statement

The authors reported no conflict of interest related to this work. DLP, PT, FB, VT, FL, PV, SA, BL, XD, ASL, NF, CV, SA, FG, VF, GL, VF, GL, NL, ZL have nothing to disclose. PL reports personal fees and non-financial support from Pfizer, personal fees and non-financial support from Sanofi Pasteur, outside the submitted work. OL reports personal fees and non-financial support from Janssen, personal fees and non-financial support from MSD, personal fees and non-financial support from Sanofi Pasteur, personal fees and non-financial support from GSK, personal fees and non-financial support from Pfizer, outside the submitted work. SJ reports personal fees from Actelion, personal fees from AIRB, personal fees from AstraZeneca, personal fees from Bristol-Myers Squibb, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from Galecto, personal fees from Gilead, personal fees from GlaxoSmithKline, personal fees from LVL, personal fees from Mundipharma, personal fees from Novartis, personal fees from Pfizer, personal fees from Roche, personal fees from Savara-Serendex, outside the submitted work.

Figures

Figure 1
Figure 1
Study flow chart. ILI influenza-like illness, ICS inhaled corticosteroids.
See this image and copyright information in PMC

References

    1. Husta BC, Raoof S, Erzurum S, Mehta AC. Tracheobronchopathy from inhaled corticosteroids. Chest. 2017;152:1296–1305. doi: 10.1016/j.chest.2017.08.013. - DOI - PMC - PubMed
    1. Fergeson JE, Patel SS, Lockey RF. Acute asthma, prognosis, and treatment. J. Allergy Clin. Immunol. 2017;139:438–447. doi: 10.1016/j.jaci.2016.06.054. - DOI - PubMed
    1. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob. Health Epidemiol. Genomics. 2018 doi: 10.1017/gheg.2018.1. - DOI - PMC - PubMed
    1. Varmaghani M, et al. Global prevalence of chronic obstructive pulmonary disease: Systematic review and meta-analysis. East. Mediterr. Health J. 2019;25:47–57. doi: 10.26719/emhj.18.014. - DOI - PubMed
    1. The FLUVAC Study Group Non-influenza respiratory viruses in adult patients admitted with influenza-like illness: A 3-year prospective multicenter study. Infection. 2020 doi: 10.1007/s15010-019-01388-1. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances